ADT With GnRH Antagonists in Prostate Cancer

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Michael J. Morris, MD, discusses the FDA approval of lutetium Lu 177 vipivotide tetraxetan plus an ARPI in PSMA+ mHSPC.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.

Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.